FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1628298331> ?p ?o ?g. }

• W1628298331 endingPage "68" @default.
• W1628298331 startingPage "55" @default.
• W1628298331 abstract "The treatment options currently available in the medical therapy of advanced colorectal cancer (CRC) appear to be an abundance of riches. The integration of oxaliplatin and irinotecan as conventional cytotoxic agents as well as bevacizumab and the epidermal growth factor receptor (EGFR) antibodies, cetuximab and panitumumab, as novel targeted agents into standard medical therapy have improved median overall survival in metastatic CRC beyond 2 years. It cannot be overemphasized that these significant improvements in outcome of patients with CRC are closely linked to the number of active drugs available to treat this disease. The abundance of treatment options, however, comes with specific challenges for the practical management of palliative medical therapy in advanced CRC, in particular with regard to the utilization of targeted agents. In this context, bevacizumab has established itself as the standard component of first-line chemotherapy. It is of interest for clinical practice that so far no predictive marker for the activity of bevacizumab in metastatic CRC has been identified. The key questions surrounding the use of bevacizumab in the palliative setting are whether its continuation beyond tumor progression provides clinical benefit, and which patient group is at higher risk for bevacizumab-related toxicities. Cetuximab and panitumumab have demonstrated efficacy both in combination with chemotherapy or — in contrast to bevacizumab — as single agent. In unselected patients, the effect of both EGFR antibodies on time-related parameters, progression free survival and overall survival, is moderate at best with emphasis more on the induction of tumor responses in a select group of patients. Therefore, until recently, EGFR antibodies were mainly regarded as salvage therapy options, in particular, since there did not appear to be a loss of activity when used in later lines of therapy. The finding that CRC harboring KRAS (and BRAF) mutations are resistant to EGFR antibodies, has allowed us to enrich the patient population with CRC that have a chance to benefit from cetuximab or panitumumab therapy. Biomarker-based treatment decisions are therefore now an integral part of clinical practice and trial design in CRC. In conclusion, targeted agents have become an integral part of medical therapy for advanced CRC. The challenge for current oncologic practice is to develop a rationale and biomarker-based treatment algorithm utilizing all potentially active agents as individualized therapy." @default.
• W1628298331 created "2016-06-24" @default.
• W1628298331 creator A5057458005 @default.
• W1628298331 date "2009-08-18" @default.
• W1628298331 modified "2023-09-23" @default.
• W1628298331 title "Review: Medical treatment of advanced colorectal cancer in 2009" @default.
• W1628298331 cites W1847455118 @default.
• W1628298331 cites W1874410314 @default.
• W1628298331 cites W1910716144 @default.
• W1628298331 cites W1919810009 @default.
• W1628298331 cites W1941365207 @default.
• W1628298331 cites W1970843783 @default.
• W1628298331 cites W1979423262 @default.
• W1628298331 cites W1985035689 @default.
• W1628298331 cites W1988901044 @default.
• W1628298331 cites W1999250974 @default.
• W1628298331 cites W2002226820 @default.
• W1628298331 cites W2006824814 @default.
• W1628298331 cites W2043103956 @default.
• W1628298331 cites W2044792687 @default.
• W1628298331 cites W2051224942 @default.
• W1628298331 cites W2066040529 @default.
• W1628298331 cites W2067296180 @default.
• W1628298331 cites W2071258820 @default.
• W1628298331 cites W2082818260 @default.
• W1628298331 cites W2083695927 @default.
• W1628298331 cites W2084470612 @default.
• W1628298331 cites W2085705101 @default.
• W1628298331 cites W2092215947 @default.
• W1628298331 cites W2093531978 @default.
• W1628298331 cites W2096122707 @default.
• W1628298331 cites W2096134439 @default.
• W1628298331 cites W2097121246 @default.
• W1628298331 cites W2100589633 @default.
• W1628298331 cites W2101711321 @default.
• W1628298331 cites W2102601598 @default.
• W1628298331 cites W2106475544 @default.
• W1628298331 cites W2106656437 @default.
• W1628298331 cites W2106789440 @default.
• W1628298331 cites W2106845199 @default.
• W1628298331 cites W2109498035 @default.
• W1628298331 cites W2112270226 @default.
• W1628298331 cites W2112727687 @default.
• W1628298331 cites W2113818241 @default.
• W1628298331 cites W2114271871 @default.
• W1628298331 cites W2114857812 @default.
• W1628298331 cites W2115366398 @default.
• W1628298331 cites W2121313610 @default.
• W1628298331 cites W2121368761 @default.
• W1628298331 cites W2123133140 @default.
• W1628298331 cites W2125447919 @default.
• W1628298331 cites W2127640925 @default.
• W1628298331 cites W2128403792 @default.
• W1628298331 cites W2128447158 @default.
• W1628298331 cites W2131413118 @default.
• W1628298331 cites W2131745440 @default.
• W1628298331 cites W2133399075 @default.
• W1628298331 cites W2136055188 @default.
• W1628298331 cites W2138235363 @default.
• W1628298331 cites W2140035322 @default.
• W1628298331 cites W2142564546 @default.
• W1628298331 cites W2143743735 @default.
• W1628298331 cites W2154662994 @default.
• W1628298331 cites W2155311724 @default.
• W1628298331 cites W2157416388 @default.
• W1628298331 cites W2157769714 @default.
• W1628298331 cites W2162313061 @default.
• W1628298331 cites W2164837623 @default.
• W1628298331 cites W2166573361 @default.
• W1628298331 cites W2168213749 @default.
• W1628298331 cites W2168377135 @default.
• W1628298331 cites W2168460655 @default.
• W1628298331 cites W2274948752 @default.
• W1628298331 cites W2314927739 @default.
• W1628298331 cites W2409420104 @default.
• W1628298331 cites W2589823065 @default.
• W1628298331 doi "https://doi.org/10.1177/1758834009343302" @default.
• W1628298331 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3125994" @default.
• W1628298331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21789113" @default.
• W1628298331 hasPublicationYear "2009" @default.
• W1628298331 type Work @default.
• W1628298331 sameAs 1628298331 @default.
• W1628298331 citedByCount "7" @default.
• W1628298331 countsByYear W16282983312013 @default.
• W1628298331 countsByYear W16282983312015 @default.
• W1628298331 countsByYear W16282983312016 @default.
• W1628298331 countsByYear W16282983312017 @default.
• W1628298331 countsByYear W16282983312022 @default.
• W1628298331 crossrefType "journal-article" @default.
• W1628298331 hasAuthorship W1628298331A5057458005 @default.
• W1628298331 hasBestOaLocation W16282983311 @default.
• W1628298331 hasConcept C121608353 @default.
• W1628298331 hasConcept C126322002 @default.
• W1628298331 hasConcept C143998085 @default.
• W1628298331 hasConcept C151730666 @default.
• W1628298331 hasConcept C2776694085 @default.
• W1628298331 hasConcept C2777802072 @default.
• W1628298331 hasConcept C2778332735 @default.

• next